RHHBY - Genentech's Hemlibra shows favorable safety and efficacy in people with hemophilia A

Genentech, a member of the Roche Group (OTCQX:RHHBY) announces results from an interim analysis of the Phase III HAVEN 6 study, which show Hemlibra (emicizumab-kxwh) demonstrated a favorable safety profile and effective bleed control in people with moderate or mild hemophilia A without factor VIII inhibitors. This interim analysis was conducted after 50 participants completed at least 24 weeks in the study or withdrew. Data cutoff was on April 16, 2021. These data show Hemlibra demonstrated a favorable safety profile and effective bleed control in the HAVEN 6 study, with 80.3% of participants experiencing no bleeding episodes that required treatment and 90.1% experiencing no joint bleeds that required treatment. Annualized bleeding rates remained low, consistent with previously reported observations. In addition, of the 50 participants aged 12 years or older, 96%  preferred Hemlibra to their previous treatment. The data were presented at the 63rd American Society of Hematology Annual Meeting and

For further details see:

Genentech's Hemlibra shows favorable safety and efficacy in people with hemophilia A